
-
Collegium Pharmaceutical NasdaqGS:COLL Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Location: 100 Technology Center Drive, Stoughton, MA, 02072, United States | Website: https://www.collegiumpharma.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.706B
Cash
197.8M
Avg Qtr Burn
N/A
Short % of Float
18.63%
Insider Ownership
1.69%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nucynta (tapentadol) Tablets / Extended-Release Tablets Details Pain, Acute pain | Approved Quarterly sales | |
Approved Quarterly sales | ||
Belbuca (Buprenorphine) Details Chronic pain | Approved Quarterly sales | |
Xtampza ER (oxycodone) Details Pain, Acute pain | Approved Quarterly sales | |
Symproic (naldemedine) Details Opioid induced constipation, Bowel preparation | Approved Quarterly sales |